Want to see FR:ALTHE full AI Analyst Report?
ALTHE Stock Chart & Stats
€0.59
<€0.01(<0.01%)
At close: 4:00 PM EDT
€0.59
<€0.01(<0.01%)
Day’s Range― - ―
52-Week Range€0.40 - €1.25
Previous CloseN/A
Volume57.25K
Average Volume (3M)82.89K
Market Cap
€43.34M
Enterprise Value€37.71
Total Cash (Recent Filing)€3.38M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Oct 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding73,123,314
10 Day Avg. Volume39,747
30 Day Avg. Volume82,891
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-13.53
Price to Sales (P/S)29.53
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized HIFU TechnologyTheraclion’s Echopulse is an imaging-guided HIFU platform for non-invasive ultrasound therapies. That focused technology and procedure-based positioning creates a durable product moat in a specialized medical-device niche, supporting long-term clinical adoption and a differentiated offering.
Recent Top-line MomentumReported revenue growth (~42.9%) indicates historical top-line momentum and potential market traction for its devices. If sustained, such growth supports scale economies, better absorption of fixed costs, and a clearer path toward improving margins over a multi-quarter horizon.
Lean Operating FootprintA headcount of 36 points to a lean cost structure and operational agility. A small, focused team can preserve cash, adapt R&D or go-to-market priorities quickly, and extend runway—advantages that help manage burn while executing commercialization and clinical activities.
Bears Say
Structural UnprofitabilityFinancials show gross, operating, and net losses across reported years, indicating structural unprofitability. Continued negative margins erode internal capital, necessitate repeated external funding or severe cost cuts, and make sustainable profitability contingent on material revenue gains or restructuring.
High Cash BurnOperating and free cash flow are persistently negative, with around -€7.2M in 2025, reflecting material cash burn. Persistent outflows force reliance on external financing, constrain strategic investments in commercialization or R&D, and increase execution and refinancing risk over the medium term.
Balance-sheet And Leverage StrainRecurring negative equity and meaningful debt relative to a small revenue base elevate solvency risk and limit financial flexibility. High leverage versus revenue reduces access to low-cost capital, increases refinancing/dilution risk, and constrains the company’s ability to fund growth without dilutive or expensive financing.
ALTHE FAQ
What was Theraclion SA’s price range in the past 12 months?
Theraclion SA lowest stock price was €0.40 and its highest was €1.25 in the past 12 months.
What is Theraclion SA’s market cap?
Theraclion SA’s market cap is €43.34M.
When is Theraclion SA’s upcoming earnings report date?
Theraclion SA’s upcoming earnings report date is Oct 14, 2026 which is in 78 days.
How were Theraclion SA’s earnings last quarter?
Theraclion SA released its earnings results on Apr 16, 2026. The company reported -€0.053 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Theraclion SA overvalued?
According to Wall Street analysts Theraclion SA’s price is currently Overvalued.
Does Theraclion SA pay dividends?
Theraclion SA does not currently pay dividends.
What is Theraclion SA’s EPS estimate?
Theraclion SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theraclion SA have?
Theraclion SA has 73,123,314 shares outstanding.
What happened to Theraclion SA’s price movement after its last earnings report?
Theraclion SA reported an EPS of -€0.053 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.427%.
Which hedge fund is a major shareholder of Theraclion SA?
Currently, no hedge funds are holding shares in FR:ALTHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theraclion SA
Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a robotic, non-surgical echotherapy system designed for addressing varicose veins, and ECHOPULSE, a similar robotic, non-invasive solution for treating thyroid nodules and breast fibroadenoma. Furthermore, the company provides EPack, a disposable component used during procedures to protect the patient's skin and enhance image clarity.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Novacyt
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―